Related Experiment Videos
Immunotherapy for Esophageal Squamous Cell Carcinoma
Takashi Kojima1, Toshihiko Doi2
1Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Current Oncology Reports
|April 1, 2017
Summary
Treating esophageal squamous cell carcinoma remains challenging. Immunotherapy, including immune checkpoint inhibitors like pembrolizumab and nivolumab, shows promise for improving survival rates.
Area of Science:
- Oncology
- Immunology
Background:
- Esophageal squamous cell carcinoma (ESCC) treatment has historically yielded limited survival improvements.
- Novel therapeutic strategies are urgently needed for this challenging malignancy.
Purpose of the Study:
- To review the current landscape and emerging strategies in the treatment of esophageal squamous cell carcinoma.
- To highlight the potential of immunotherapy and combination approaches.
Main Methods:
- Review of recent clinical studies and preclinical research on immunotherapy for ESCC.
- Analysis of immune checkpoint inhibitors, adoptive T cell therapy, vaccines, and oncolytic viruses.
- Exploration of combination therapies, particularly with radiation.
Main Results:
- Early studies of immune checkpoint inhibitors (pembrolizumab, nivolumab) demonstrate encouraging efficacy in ESCC.
- Investigational therapies like anti-chemokine receptors and oncolytic viruses show progress.
- Combination of immune checkpoint inhibitors with radiation therapy is anticipated to yield improved outcomes.
Conclusions:
- Immunotherapy represents a promising avenue for advancing ESCC treatment.
- Further development of adoptive T cell therapy and vaccines is ongoing.
- A multidisciplinary approach is crucial for optimizing patient care and outcomes in ESCC.